tert-butyl (4R,5R)-4-[(E)-5-[(4R,5R)-2,2-dimethyl-3-[(2-methylpropan-2-yl)oxycarbonyl]-5-phenyl-1,3-oxazolidin-4-yl]-5-hydroxy-4-[4-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]-3-oxopent-1-enyl]-2,2-dimethyl-5-phenyl-1,3-oxazolidine-3-carboxylate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl (4R,5R)-4-[(E)-5-[(4R,5R)-2,2-dimethyl-3-[(2-methylpropan-2-yl)oxycarbonyl]-5-phenyl-1,3-oxazolidin-4-yl]-5-hydroxy-4-[4-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]-3-oxopent-1-enyl]-2,2-dimethyl-5-phenyl-1,3-oxazolidine-3-carboxylate
• 化学式: C₄₈H₆₃N₃O₁₀
• 分子量: 842.0
• InChiKey: LGXLHOXMJZSDPV-XBYUGVQZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.4
• 重原子数：
  61
• 可旋转键数：
  15
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  153
• 氢给体数：
  2
• 氢受体数：
  10

文献信息

• Process for making beta 3 agonists and intermediates
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10435410B2

  公开（公告）日：2019-10-08

  The present invention is directed to processes for preparing beta 3 agonists of Formula (I) and Formula (II) and their intermediates. The beta 3 agonists are useful in the treatment of certain disorders, including overactive bladder, urinary incontinence, and urinary urgency.

  本发明涉及制备式（I）和式（II）β3 激动剂及其中间体的工艺。β3激动剂可用于治疗某些疾病，包括膀胱过度活动症、尿失禁和尿急。
• PROCESS FOR MAKING BETA 3 AGONISTS AND INTERMEDIATES
  申请人：Chung John Y.L.

  公开号：US20140242645A1

  公开（公告）日：2014-08-28

  The present invention is directed to a process for preparing a compound of formula I-11 through multiple-step reactions.
• Process for Making Beta 3 Agonists and Intermediates
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20160176884A1

  公开（公告）日：2016-06-23

  The present invention is directed to processes for preparing beta 3 agonists of Formula (I) and Formula (II) and their intermediates. The beta 3 agonists are useful in the treatment of certain disorders, including overactive bladder, urinary incontinence, and urinary urgency.
• US9822121B2
  申请人：——

  公开号：US9822121B2

  公开（公告）日：2017-11-21
• US9809536B2
  申请人：——

  公开号：US9809536B2

  公开（公告）日：2017-11-07